Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammatory Disease, Pain Management, and Neurological Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PTGER3 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PTGER3 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View PTGER3 Products |
| Gene Delivery | PTGER3 Lentivirus Particles Full-length ORF for stable GPCR cell lines. Native conformation preservation. |
View PTGER3 Products |
| Gene ORF | PTGER3 Promise-ORF Codon-optimized for mammalian expression. Sequence Verified. |
View PTGER3 Products |
| Benchmark Ab | Anti-PTGER3 Reference Antibody Recombinant positive control for assay development. |
View PTGER3 Products |
| Validator | PTGER3 siRNA Set For knockdown verification and specificity controls. |
View PTGER3 Products |
| Related Target (Pathway) | PTGS2 (COX-2) Upstream PGE2 synthesis enzyme. Critical for combination studies. |
View PTGS2 Products |
| Related Target (Selectivity) | PTGER4 (EP4) Counter-screening receptor. High homology, requires selectivity testing. |
View PTGER4 Products |
| Related Target (Family) | PTGER1 (EP1) Parallel pathway validation. Cardiovascular safety assessment. |
View PTGER1 Products |
| Related Target (Counter-screen) | PTGER2 (EP2) Additional counter-screening target to ensure subtype selectivity. |
View PTGER2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GPCR Conformational Integrity | Lentivirus-encoded full-length receptor. Maintains native glycosylation and membrane topology in HEK293 cells. |
| EP Receptor Family Selectivity | Human EP1/EP2/EP3/EP4 ortholog panel available. Sequence Verified by mass spec for off-target screening. |
| Cross-species Preclinical Translation | Human/Mouse/Rat/Cyno PTGER3 lentivirus systems. Enable species-specific pharmacokinetic modeling. |
| False Positive Elimination | Validated siRNA included for receptor-specific signal verification. |
| Lack of Controls | Clinical Benchmark Antibodies included for assay validation. |
Live PTGER3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- View Active Clinical Trials
- Latest Antagonist Research
- Latest Resistance Research
- Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for PTGER3 therapeutics represents a strategic pivot toward GPCR-targeted analgesics that circumvent the gastrointestinal liabilities of traditional NSAIDs and the addiction risks of opioids. Current development focuses on subtype-selective antagonists to block the pro-inflammatory EP3 signaling while preserving the cytoprotective functions of EP2/EP4 receptors. As first-generation small molecules advance through Phase I/II for pain and migraine indications, the next wave of R&D is targeting combination strategies with COX-2 inhibitors (PTGS2) and extended-release formulations for chronic inflammatory conditions. Additionally, PTGER3 involvement in metabolic disorders (e.g., obesity, diabetes) is opening avenues for agonist peptide development.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Antagonists | Ono Pharmaceutical, Bayer, Arena | Chronic Pain, Migraine, Dysmenorrhea | Cell-based cAMP inhibition assays using lentivirus-stable lines |
| Selective Modulators | Eli Lilly, Daiichi Sankyo | Inflammatory Bowel Disease | EP1/EP2/EP3/EP4 selectivity panel for GI safety |
| Combination Therapy | Pfizer, Merck | Arthritis, Cardiovascular Protection | Dual-target assays (PTGER3 + PTGS2) with compatible cell lines |
| Monoclonal Antibody | Emerging Biotechs | Chronic Inflammation | Functional Binding Assay (Need Native conformation cell lines) |
| Agonist Peptides | Various | Metabolic Disorders | cAMP/Calcium Flux (Need strictly controlled expression) |
Genetic Polymorphisms and Functional Variants
Known natural variants in PTGER3 include rs5670 (UniProt VAR_014694), rs13306020 (UniProt VAR_049436), and rs13306014 (UniProt VAR_029218). These single nucleotide polymorphisms may affect receptor expression or signaling and should be considered in disease association studies and drug development.